Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?

Key Takeaways Alnylam reported $2.99B in 2025 net product revenues, up 81% YoY, driven by four approved drugs.ALNY's cemdisiran hit key phase III endpoints in generalized MG, with partner Regeneron planning U.S. filing.Zilebesiran and mivelsiran advance in late and mid-stage studies, targeting cardiovascular and AD markets.Alnylam Pharmaceuticals (ALNY) currently markets four approved drugs — Onpattro, Givlaari, Oxlumo and Amvuttra — that together generated $2.99 billion in net product revenues, representin ...